- Home
- ACLX
ACLX
Arcellx Inc.
as 12-06-2024 4:00pm EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 5.3B | IPO Year: | 2022 |
| Target Price: | $103.67 | AVG Volume (30 days): | 466.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $46.42 - $107.37 | Next Earning Date: | 11-07-2024 |
| Revenue: | $155,818,000 | Revenue Growth: | 230.33% |
| Revenue Growth (this year): | 10.41% | Revenue Growth (next year): | -9.43% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Kavita | ACLX | Director | Dec 3 '24 | Sell | $92.02 | 1,500 | $137,817.72 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Nov 15 '24 | Sell | $90.93 | 1,761 | $156,508.43 | 100 | |
| Patel Kavita | ACLX | Director | Nov 12 '24 | Sell | $106.33 | 1,500 | $159,495.00 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Nov 8 '24 | Sell | $101.29 | 12,354 | $1,242,170.45 | 100 | |
| Patel Kavita | ACLX | Director | Nov 7 '24 | Sell | $102.92 | 57,479 | $5,971,808.80 | 0 | |
| Patel Kavita | ACLX | Director | Oct 22 '24 | Sell | $89.69 | 1,500 | $134,535.00 | 0 | |
| Patel Kavita | ACLX | Director | Oct 1 '24 | Sell | $82.24 | 1,500 | $123,360.00 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Sep 17 '24 | Sell | $77.69 | 15,000 | $1,165,879.57 | 100 | |
| Patel Kavita | ACLX | Director | Sep 10 '24 | Sell | $74.41 | 1,500 | $111,615.00 | 0 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Zacks
23 days ago
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice
MT Newswires
24 days ago
Arcellx Insider Sold Shares Worth $1,242,170, According to a Recent SEC Filing
Simply Wall St.
a month ago
Arcellx Third Quarter 2024 Earnings: Misses Expectations
Zacks
a month ago
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
Zacks
a month ago
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
Business Wire
a month ago
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
TipRanks
a month ago
Arcellx price target raised to $106 from $81 at Morgan Stanley
Zacks
a month ago
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.